Autres langues Roivant Sciences Ltd.

Actions

ROIV

BMG762791017

Temps réel estimé Cboe BZX Autres places de cotation 17:59:22 12/06/2024			Varia. 5j.	Varia. 1 janv.
10,78 ^USD	+1,94 %		-0,92 %	-4,01 %

10/06	Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:40 AM
05/06	Transcript : Roivant Sciences Ltd. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:30 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Roivant Sciences Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024	30/05
Roivant Sciences : 4Q2023 Earnings Call Presentation	30/05
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises	30/05
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia Down, Europe Rises	30/05
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	30/05
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	30/05
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	30/05
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	16/05
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05/04
Moderna Suffers Setback in Lawsuit by Arbutus	04/04
Moderna shares fall after judge sides with Arbutus in patent fight	03/04
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	02/04
Roivant Sciences : NIU Phase 2 Topline Results	02/04
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	02/04
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	02/04
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	02/04
Roivant's anti-inflammatory drug succeeds in mid-stage study	02/04
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU	02/04
Roivant Sciences Ltd. authorizes a Buyback Plan.	02/04
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000	01/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Roivant Sciences Ltd.

Actions

ROIV

BMG762791017

Autres langues

Filtres